[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572515":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Rush University Medical Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SG-T: sleeve gastrectomy with tirzepatide","EXPERIMENTAL","In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months after surgery they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.",[13,14],"Drug: Mounjaro","Procedure: Sleeve Gastrectomy",{"label":16,"type":17,"description":18,"interventionNames":19},"SG-A: sleeve gastrectomy alone","ACTIVE_COMPARATOR","In this study the control group (n=21) are patients who will undergo sleeve gastrectomy alone.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Mounjaro","In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"PROCEDURE","Sleeve Gastrectomy","Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.",[16,9],[33],{"name":34,"affiliation":5,"role":35},"Nicholas Skertich, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Research Administrator","CONTACT","312-942-5500","anna_t_alecci@rush.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Chicago","Illinois","60612","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-87.65005,41.85003,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":40,"phoneExt":26,"email":59},"Sr. Clinical Research Coordinator","matthew_johnson@rush.edu",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Nicholas Skertich","Assistant Professor","100572515","early-phase-1-randomized-control-trial-of-sleeve-gastrectomy-with-tirzepatide-in-maximizing-weight-loss-100572515",false,"NCT06734273","Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss","Inclusion Criteria:\n\n* Adult 18 to 65 years of age\n* Body Mass Index \\>35 with comorbidity of Type 2 Diabetes and\u002For Hypertension and\u002For Hyperlipidemia and\u002For Obstructive Sleep Apnea OR Body Mass Index \\>40 with or without comorbidity\n* Undergoing primary sleeve gastrectomy\n\nExclusion Criteria:\n\n* Prior metabolic and bariatric surgery\n* Prior use of GLP-1 agonist\n* Prior history of pancreatitis\n* Personal\u002Ffamily history of medullary thyroid cancer or MEN type 2\n* Secondary cause of obesity\n* Any eating disorder\n* Pregnancy\u002Flactation\n* History of acute coronary syndrome or myocardial infarction\n* History of stroke\n* Hepatic dysfunction: AST\u002FALT \\>3 ULN\n* Renal dysfunction eGFR\\\u003C45ml\u002Fmin\u002F1.73m2\n* Active malignancy\n* History of diabetic retinopathy\n* History of gastroparesis","ALL","18 Years","65 Years",{"count":74,"type":75},42,"ESTIMATED","INTERVENTIONAL",[78],"EARLY_PHASE1","This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.",[81],"Obesity and Obesity-related Medical Conditions","2026-05-05",{"date":84,"type":85},"2026-05-08","ACTUAL",{"date":87,"type":85},"2025-03-10",{"date":89,"type":75},"2028-09",{"name":62,"class":6},1]